Response Guided Slow Infusion of Albumin, Vasoconstrictors and Furosemide Improves Ascites Mobilization and Survival in Acute on Chronic Liver Failure: A Proof-of-Concept Study

References

• Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms, and management. Nat Rev Gastroenterol Hepatol. 2016;13(3):131–149. doi:10.1038/nrgastro.2015.219
   PubMed Web of Science ®Google Scholar
• Garg H, Kumar A, Garg V, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol. 2013;28:1361–1367.
   PubMed Web of Science ®Google Scholar
• Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553.
   PubMed Web of Science ®Google Scholar
• Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–1437.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo J, Qian G, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol. 2015;30:1429–1437.
   PubMed Web of Science ®Google Scholar
• Cariello R, Federico A, Sapone A, et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig Liver Dis. 2010;42:200–204.
   PubMedGoogle Scholar
• Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transplant. 2004;10:1109–1119.
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Sen S, Davies NA, Hodges SJ, Williams R, Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut. 2003;52:1182–1187.
   PubMed Web of Science ®Google Scholar
• Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64:1249–1264.
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46(3):831–840. doi:10.1002/hep.21737
   PubMed Web of Science ®Google Scholar
• Markwick LJ, Riva A, Ryan JM, et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology. 2015;148(3):590–602.e10. doi:10.1053/j.gastro.2014.11.041
   PubMed Web of Science ®Google Scholar
• Martin-Mateos R, Alvarez-Mon M, Albillos A. Dysfunctional immune response in acute-on-chronic liver failure: it takes two to tango. Front Immunol. 2019;10:973.
   PubMed Web of Science ®Google Scholar
• Lodato F, Berzigotti A, Lisotti A, et al. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. Scand J Gastroenterol. 2012;47:1494–1500.
   PubMed Web of Science ®Google Scholar
• Lautt WW. Hepatic Circulation: Physiology and Pathophysiology. San Rafael (CA): Morgan & Claypool Life Sciences; 2009.
   Google Scholar
• Baik SK, Jeong PH, Ji SW, et al. Acute hemodynamic effect of octreotide and terlipressin in patients with cirrhosis: a randomised comparison. Am J Gastroenterol. 2005;100:631–635.
   PubMed Web of Science ®Google Scholar
• Runyon BA. Refractory ascites. Semin Liver Dis. 1993;13:343.
   PubMed Web of Science ®Google Scholar
• Jackson EK. Drugs affecting renal excretory function. In: LL Brunton, editor. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 13th ed. McGraw Hill; 2018:445–470.
   Google Scholar
• Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 1987;32:198–203.
   PubMed Web of Science ®Google Scholar
• Schetz M. Loop diuretics. In: Ronco C, Bellomo R, Kellum. JA, editors. Critical Care Nephrology. Saunders; 2008:547–551.
   Google Scholar
• Ilyas A, Ishtiaq W, Assad S, et al. Correlation of IVC diameter and collapsibility index with central venous pressure in the assessment of intravascular volume in critically ill patients. Cureus. 2017. 9: e1025.
   PubMedGoogle Scholar
• Zhang Z, Xu X, Ye S, Xu L. Ultrasonographic measurement of the respiratory variation in the inferior vena cava diameter is predictive of fluid responsiveness in critically ill patients: systematic review and meta-analysis. Ultrasound Med Biol. 2014;40:845–853.
   PubMed Web of Science ®Google Scholar
• Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, et al. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014;39:543–552.
   PubMed Web of Science ®Google Scholar
• Szabó M, Bozó A, Darvas K, Horváth A, Iványi ZD. Role of inferior vena cava collapsibility index in the prediction of hypotension associated with general anesthesia: an observational study. BMC Anesthesiol. 2019;19:139.
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice. Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
   PubMed Web of Science ®Google Scholar
• Harrison PM. Management of patients with decompensated cirrhosis. Clin Med. 2015;15:201–203.
   PubMed Web of Science ®Google Scholar
• Pudil R, Pelouch R, Praus R, Vašatová M, Hůlek P. Heart failure in patients with liver cirrhosis. Cor Vasa. 2013;55:e391–396.
   Google Scholar
• Kumar A, Das K, Sharma P, Mehta V, Sharma BC, Sarin SK. Hemodynamic studies in acute-on-chronic liver failure. Dig Dis Sci. 2009;54:869–878.
   PubMed Web of Science ®Google Scholar
• Spinella R, Sawhney R, Jalan R. Albumin in chronic liver disease: structure, functions and therapeutic implications. Hepatol Int. 2016;10:124–132.
   PubMed Web of Science ®Google Scholar
• Oettl K, Birner-Gruenberger R, Spindelboeck W, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol. 2013;59:978–983.
   PubMed Web of Science ®Google Scholar
• Fliser D, Zurbrüggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 1999;55(2):629–634.
   PubMed Web of Science ®Google Scholar
• Koda M, Murawaki Y, Kawasaki H. Renovascular resistance assessed by color Doppler ultrasonography in patients with chronic liver diseases. J Gastroenterol Hepatol. 2000;15:1424–1429.
   PubMed Web of Science ®Google Scholar
• Onwuka CC, Ayoola OO, Adekanle O, Famurewa OC, Abidoye IA. Renal arterial resistance index among subjects with liver cirrhosis in a Nigerian population. J Clin Ultrasound. 2021;49:538–545.
   PubMed Web of Science ®Google Scholar
• Wilcox CS, Testani JM, Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension. 2020;76:1045–1054.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Kumar M, Sharma BC, et al. Systemic inflammatory response syndrome in acute on chronic liver failure- relevance of ‘Golden Window’- A prospective study. J Gastroenterol Hepatol. 2017;32:1989–1997.
   PubMed Web of Science ®Google Scholar
• Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396.
   PubMed Web of Science ®Google Scholar
• Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol. 2014;20:2564–2577.
   PubMed Web of Science ®Google Scholar
• Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun. 2010;34:1–6.
   PubMed Web of Science ®Google Scholar
• Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol. 2014;60:1310–1324.
   PubMed Web of Science ®Google Scholar
• Panasiuk A, Wysocka J, Maciorkowska E, et al. Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World J Gastroenterol. 2005;11:7661–7665.
   PubMed Web of Science ®Google Scholar
• Makkar K, Tomer S, Verma N, et al. Neutrophil dysfunction predicts 90-day survival in patients with acute on chronic liver failure: a longitudinal case-control study. JGH Open. 2020;4:595–602.
   PubMed Web of Science ®Google Scholar
• Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol. 2005;42:195–201.
   PubMed Web of Science ®Google Scholar
• China L, Freemantle N, Forrest E, et al.; ATTIRE Trial Investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808–817.
   PubMed Web of Science ®Google Scholar
• Caraceni P, Tufoni M, Zaccherini G, et al.; ANSWER Study Investigators. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol. 2021;74(2):340–349.
   PubMed Web of Science ®Google Scholar
• Wang Z, Xie YW, Lu Q, et al. The impact of albumin infusion on the risk of rebleeding and in-hospital mortality in cirrhotic patients admitted for acute gastrointestinal bleeding: a retrospective study of a single institute. BMC Gastroenterol. 2020;20(1):198.
   PubMed Web of Science ®Google Scholar
• Wong F, Pappas SC, Curry MP, et al.; CONFIRM Study Investigators. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–828.
   PubMed Web of Science ®Google Scholar